Selective cytokine inhibitory drugs for treating myelodysplastic syndrome

Abstract From the Canadian patent

Methods of treating, preventing and/or managing a myelodysplastic syndrome are disclosed. Specific methods encompass the administration of a selective cytokine inhibitory drug, or a pharmaceutically acceptable salt solvate, hydrate, stereoisomer, clathrate or prodrug thereof, alone or in combination with a second active ingredient, and/or blood or cells for transplantation therapy. Specific second active ingredients are capable of affecting or improving blood cell production. Pharmaceutical compositions single unit , dosage forms, and kits suitable for use in methods of the invention are also disclosed.